Holen Sie sich die Stockscreener-App
35.50
2.72%
0.95
Schlusskurs vom Vortag:
$34.55
Offen:
$33.95
24-Stunden-Volumen:
198.81K
Relative Volume:
0.29
Marktkapitalisierung:
$2.17B
Einnahmen:
$87.56M
Nettoeinkommen (Verlust:
$-167.47M
KGV:
-15.17
EPS:
-2.34
Netto-Cashflow:
$-148.20M
1W Leistung:
+6.71%
1M Leistung:
+34.64%
6M Leistung:
-23.63%
1J Leistung:
-2.23%
1-Tages-Spanne:
$33.95
$35.98
1-Wochen-Bereich:
$32.75
$35.98
52-Wochen-Spanne:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
35.50 | 2.17B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.14 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.78 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
648.48 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.60 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.31 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics Inc’s results are impressive - uspostnews.com
Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX
Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Closing Figures Unveiled: Kymera Therapeutics Inc (KYMR) Drop -7.60, Closes at 27.37 - DWinneX
JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Why Kymera Therapeutics (KYMR) Stock is Moving Today - GuruFocus
Why Kymera Therapeutics Stock Crushed it This Week - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Kymera Therapeutics Inc [KYMR] Shares Rise 9.32 % on Thursday - knoxdaily.com
KYMR’s Stock Market Adventure: -16.58% YTD Growth Amidst Volatility - investchronicle.com
Daily Market Movement: Kymera Therapeutics Inc (KYMR) Sees a 9.32 Increase, Closing at 33.56 - DWinneX
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 F - GuruFocus
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 Financials | KYMR Stock News - GuruFocus
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - The Manila Times
Kymera Unveils Revolutionary Oral Drug Program Targeting Untapped Autoimmune Disease Pathway - Stock Titan
Is Kymera Therapeutics Inc (KYMR) worth investing in despite its overvalued state? - uspostnews.com
Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times
Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan
Kymera Therapeutics Inc (KYMR) Stock: A Year of Declines and Increases - investchronicle.com
Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com
Investor’s Delight: Kymera Therapeutics Inc (KYMR) Closes Strong at 33.27, Up 0.76 - DWinneX
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus
Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia
Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia
Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa
Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
(KYMR) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - The AM Reporter
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
Citigroup starts coverage of Kymera with $52 PT - TradingView
(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chiniara Ellen | Chief Legal Officer |
Mar 03 '25 |
Sale |
30.45 |
2,241 |
68,239 |
80,085 |
| Chadwick Jeremy G | Chief Operating Officer |
Mar 03 '25 |
Sale |
30.45 |
1,383 |
42,113 |
67,800 |
| Jacobs Bruce N. | Chief Financial Officer |
Mar 03 '25 |
Sale |
30.45 |
7,035 |
214,219 |
201,886 |
| Gollob Jared | Chief Medical Officer |
Mar 03 '25 |
Sale |
30.45 |
5,740 |
174,786 |
120,000 |
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):